1
|
Gradl SN, Mueller T, Ferrara S, Sheikh SE, Janzer A, Zhou HJ, Friberg A, Guenther J, Schaefer M, Stellfeld T, Eis K, Kroeber M, Nguyen D, Merz C, Niehues M, Stoeckigt D, Christian S, Zimmermann K, Lejeune P, Bruening M, Meyer H, Puetter V, Scadden DT, Sykes DB, Seidel H, Eheim A, Michels M, Haegebarth A, Bauser M. Abstract 2: Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
DHODH is a key enzyme in the biosynthesis of pyrimidines and recent studies have renewed interest in this old anti-cancer target. Here, we disclose the discovery of 4-triazolosalicylamides as inhibitors of DHODH and their structure activity relationship (SAR). The hit cluster was discovered during a phenotypic high throughput screen (HTS) of 2.5 million compounds where proliferation of H460 lung cancer cells was used as read-out. DHODH was successfully identified as the molecular target by comparing the activity profile of the hits in a panel of cell lines to a set of inhibitors with known pharmacological activity. The hit compounds showed good cellular potency but had undesirable DMPK properties. Interestingly, the compounds are non-ionizable in contrast to many other DHODH inhibitors and show no potency shift from biochemical to cellular assays. Structural modifications lead to compounds with sub-nanomolar potency in cellular assays and increased metabolic stability enabling the proof of concept in vivo xenograft experiments. Further optimization guided by lipophilicity efficiency and identification of metabolic hot spots resulted in molecules with low clearance and improved solubility. BAY 2402234 was selected as the clinical candidate after side by side comparison of a number of promising compounds. It shows great oral bioavailability, target engagement in all preclinical species tested, induces differentiation in AML models, and has excellent activity in a variety of leukemia models. A clinical phase I study has been initiated in patients with myeloid malignancies. (NCT03404726)
Citation Format: Stefan N. Gradl, Thomas Mueller, Steven Ferrara, Sherif El Sheikh, Andreas Janzer, Han-Jie Zhou, Anders Friberg, Judith Guenther, Martina Schaefer, Timo Stellfeld, Knut Eis, Michael Kroeber, Duy Nguyen, Claudia Merz, Michael Niehues, Detlef Stoeckigt, Sven Christian, Katja Zimmermann, Pascal Lejeune, Michael Bruening, Hanna Meyer, Vera Puetter, David T. Scadden, David B. Sykes, Henrik Seidel, Ashley Eheim, Martin Michels, Andrea Haegebarth, Marcus Bauser. Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Knut Eis
- 1Bayer AG, Pharmaceuticals Division, Berlin, Germany
| | | | - Duy Nguyen
- 1Bayer AG, Pharmaceuticals Division, Berlin, Germany
| | - Claudia Merz
- 1Bayer AG, Pharmaceuticals Division, Berlin, Germany
| | | | | | | | | | | | | | - Hanna Meyer
- 1Bayer AG, Pharmaceuticals Division, Berlin, Germany
| | - Vera Puetter
- 1Bayer AG, Pharmaceuticals Division, Berlin, Germany
| | | | | | - Henrik Seidel
- 1Bayer AG, Pharmaceuticals Division, Berlin, Germany
| | - Ashley Eheim
- 1Bayer AG, Pharmaceuticals Division, Berlin, Germany
| | | | | | - Marcus Bauser
- 1Bayer AG, Pharmaceuticals Division, Berlin, Germany
| |
Collapse
|
2
|
Helbig L, Simank HG, Kroeber M, Schmidmaier G, Grützner PA, Guehring T. Core decompression combined with implantation of a demineralised bone matrix for non-traumatic osteonecrosis of the femoral head. Arch Orthop Trauma Surg 2012; 132:1095-103. [PMID: 22566110 DOI: 10.1007/s00402-012-1526-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2011] [Indexed: 02/09/2023]
Abstract
INTRODUCTION Core decompression is the standard surgical procedure in the treatment of early stage non-traumatic osteonecrosis of the femoral head (ONFH). However, there is still a debate whether decompression in combination with supplementary augmentation by bone grafts, growth factors, or cell implementation is superior to conventional decompression alone. This study evaluated patients after core decompression combined with an augmentation by a demineralised bone matrix, and particularly aimed to report long-term conversion rates to total hip replacement (THR). MATERIALS AND METHODS 14 patients with 18 hips suffering from ONFH (Ficat stage I-IIB) underwent this surgical procedure. All patients underwent radiographic and MRI investigations at baseline and at follow-up periods of 12 and 24 months. The clinical follow-up was done using the Merle d'Aubigné-score for an average period of 9 years after surgery. RESULTS 14 of the 18 subjects (77 %) achieved at least a good clinical result after 2 years. The Merle d'Aubigné-score improved significantly after 12 (p = 0.0001) and 24 months (p = 0.0002). However, the MRI volumetric analysis showed an increased necrotic bone volume from 3.16 ± 0.54 to 3.88 ± 0.62 cm(3) (p = 0.04). Within 9 years, 13 out of 18 cases (72 %) required further surgery by THR. Only 7 out of 18 subjects (39 %) reported an ongoing postoperative clinical benefit, and would retrospectively redo the same surgical approach again. The five patients that did not require THR were still satisfied after 9 years. CONCLUSIONS In patients with early- stage femoral head osteonecrosis core decompression combined with the implantation of a demineralised bone matrix leads to a limited, temporary pain relief as seen in core decompression alone. However, long-term results were not encouraging with a high rate of conversion to arthroplasty. Therefore, core decompression with implantation of a demineralised bone matrix may be not appropriate to avoid THR in the long term.
Collapse
Affiliation(s)
- L Helbig
- Department für Orthopädie, Unfallchirurgie und Paraplegiologie, Universitätsklinik Heidelberg, Schlierbacher Landstrasse 200a, 69118, Heidelberg, Germany.
| | | | | | | | | | | |
Collapse
|